HIGHLIGHTS
- who: Henry G. Kaplan from the Swedish Cancer Institute, East Madison, Seattle, WA, USA have published the research: Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999-2018, in the Journal: (JOURNAL)
- what: The aim of the real -world retrospective cohort study was to assess the relationship between trastuzumab treatment duration and patient outcomes among de novo MBC HER2-positive patients at the Swedish Cancer Institute. This study was issued exemption status and approval by the Swedish Cancer Institute IRB program as the data are de-identified for analytic and study purposes . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.